Stevanato Group S.p.A. published the transcript of its “Fourth Quarter and Full Year 2025 Financial Results Conference Call,” held on March 4, 2026. The call was attended by Chairman and Chief Executive Officer Franco Stevanato, Chief Financial Officer Marco Dal Lago, and Chief Communication Officer Lisa Miles. Management reviewed 2025 performance, discussed market dynamics—particularly demand tied to GLP-1 therapies—and provided 2026 guidance. The company said 2025 revenue increased 9% at constant currency (7% reported), driven by double-digit growth in the Biopharmaceutical and Diagnostic Solutions segment and a surge in high-value solutions, while Engineering revenue declined. Stevanato highlighted continued investment and ramp-up at its Latina, Italy and Fishers, Indiana facilities, and noted capacity constraints in high-value products. “We finished fiscal 2025 with another solid quarter that led to positive full year performance and positive momentum as we start 2026,” the CEO said. On GLP-1 exposure, the CEO noted, “In fiscal 2025, our revenue from GLP1s accounted for approximately 19% to 20% of total company revenue, growing more than 50%,” adding that for 2026 the company expects GLP-1 growth “in the range of mid-teens.” The CFO set 2026 guidance at revenue of €1.260 billion to €1.290 billion, adjusted EBITDA of €331.8 million to €346.9 million, and adjusted diluted EPS of €0.59 to €0.63, while modeling breakeven to about €20 million of positive free cash flow. The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-102379), on March 11, 2026, and is solely responsible for the information contained therein.